IMPLEMENTATION LEVEL

National

AFFECTED FLOW

Outflow

ANNOUNCED AS TEMPORARY

Yes

NON-TRADE-RELATED RATIONALE

No

ELIGIBLE FIRMS

all

JUMBO

No

TARIFF PEAK

No
← back to the state act
Inception date: 05 Nov 2020 | Removal date: 31 Dec 2020

Export ban

On 5 November 2020, the Norwegian Medicines Agency introduced an export ban on immunoglobulins in the following doses: Hizentra 200 mg/ml, 20 ml hgl, Hizentra 200 mg/ml, 50 ml hgl and HyQvia 100 mg/ml, 200 ml hgl following the outbreak of COVID-19. The export ban was introduced due to concerns of local shortages. Prior to the introduction of an export ban, the pharmaceutical drug was subject to an export notification requirement, see related state act. The remaining pharmaceutical drugs were previously not subject to export restrictions by the Agency. 

Following the issuance on 6 March 2020 of Regulation FOR-2020-03-06-239 the Agency is empowered to impose export bans on these grounds. A number of export bans have already been introduced by the Norwegian Medicines Agency under Regulation FOR-2020-03-06-239.

Regulation FOR-2020-03-06-239 is in force until and including 31 December 2020. Unless revoked or withdrawn, the export ban is in force until said date. 

AFFECTED COUNTRIES

MAP
TABLE
EXPORT

AFFECTED SECTORS AND PRODUCTS

352 Pharmaceutical products
3002 Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micr
300210 Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes

Please report this page in case you detect an inaccuracy in its content.